Table 1.

Demographic, clinical, and neuropathologic characteristics of participants stratified by TDP-43 status.

Characteristic	All (n = 77)	TDP− (n = 46 (60%))	TDP+ (n = 31 (40%))	p-value
Female, n (%)	30 (39%)	17 (37%)	13 (42%)	0.81
APOE ε4 carrier, n (%)	40 (53%)	25 (54%)	15 (52%)	>0.99
Education, yr	14 (8, 20)	14 (8, 20)	16 (8, 20)	0.78
Age at last scan, yr	76 (51, 98)	74 (51, 98)	82 (55, 92)	0.08
Age at death, yr	79 (51, 99)	76 (51, 99)	84 (60, 95)	0.07
Last tau to death, yr	2.4 (0.0, 5.1)	2.2 (0.0, 4.5)	2.7 (0.6, 5.1)	0.31
Last clinical diagnosis, n (%)				0.008
CU	12 (16%)	11 (24%)	1 (3%)
MCI	8 (10%)	2 (4%)	6 (19%)
Dementia	57 (74%)	33 (72%)	24 (77%)
Braak NFT stage, n (%)				0.01
0	3 (4%)	3 (7%)	0 (0%)
I	2 (3%)	1 (2%)	1 (3%)
II	7 (9%)	6 (13%)	1 (3%)
III	6 (8%)	6 (13%)	0 (0%)
IV	8 (10%)	6 (13%)	2 (6%)
V	21 (27%)	8 (17%)	13 (42%)
VI	30 (39%)	16 (35%)	14 (45%)
Thal amyloid phase, n (%)				0.004
0	6 (8%)	6 (13%)	0 (0%)
1	4 (5%)	3 (7%)	1 (3%)
2	5 (6%)	5 (11%)	0 (0%)
3	7 (9%)	5 (11%)	2 (6%)
4	17 (22%)	9 (20%)	8 (26%)
5	37 (48%)	18 (39%)	19 (61%)
Composite Vascular, n (%)				0.008
0	4 (5%)	3 (7%)	1 (3%)
1	7 (9%)	7 (16%)	0 (0%)
2	37 (50%)	23 (52%)	14 (47%)
3	5 (7%)	5 (11%)	0 (0%)
4	21 (28%)	6 (14%)	15 (50%)

Data shown are n (%) or median (range). For categorical variables, p-values are from Fisher’s Exact Test. For continuous variables, p-values are from Wilcoxon Rank Sum test. p-values for Braak NFT stage, Thal amyloid phase, and composite vascular are from logistic regression adjusting for age at death. p-values <0.05 are considered significant and are shown in bold italics.

Abbreviations: APOE = apolipoprotein E; CU = cognitively unimpaired; MCI = mild cognitive impairment; NFT = neurofibrillary tangle